124 related articles for article (PubMed ID: 30160218)
1. Loss of Beclin1 Expression and Nrf2 Overexpression are Associated with Poor Survival of Patients with Non-Small Cell Lung Cancer.
Yu S; Cheng C; Wang J; Wang J; Qu Z; Ren H; Li Y; Ning Q; Chen M; Hu T
Anticancer Agents Med Chem; 2018; 18(12):1680-1687. PubMed ID: 30160218
[TBL] [Abstract][Full Text] [Related]
2. Reduced expression of liver kinase B1 and Beclin1 is associated with the poor survival of patients with non-small cell lung cancer.
Jiang L; Liang X; Liu M; Wang W; Ma J; Guo Q; Han L; Yang C; Nan K
Oncol Rep; 2014 Nov; 32(5):1931-8. PubMed ID: 25175672
[TBL] [Abstract][Full Text] [Related]
3. The expression of p33(ING1), p53, and autophagy-related gene Beclin1 in patients with non-small cell lung cancer.
Liu J; Lin Y; Yang H; Deng Q; Chen G; He J
Tumour Biol; 2011 Dec; 32(6):1113-21. PubMed ID: 21779982
[TBL] [Abstract][Full Text] [Related]
4. [CXCR4 and Nrf2 expressions in non-small cell lung cancer and their clinical implications].
Hu T; Yao Y; Yu S; Guo H; Tian T; Han L; Wang W; Guo Q; Wang J; Nan K; Wang S
Nan Fang Yi Ke Da Xue Xue Bao; 2014 Feb; 34(2):153-8. PubMed ID: 24589587
[TBL] [Abstract][Full Text] [Related]
5. Dual-negative expression of Nrf2 and NQO1 predicts superior outcomes in patients with non-small cell lung cancer.
Tong YH; Zhang B; Yan YY; Fan Y; Yu JW; Kong SS; Zhang D; Fang L; Su D; Lin NM
Oncotarget; 2017 Jul; 8(28):45750-45758. PubMed ID: 28501854
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and clinicopathological significance of NRF2 expression in non-small cell lung cancer: A meta-analysis.
Wang Q; Xu L; Wang G; Chen L; Li C; Jiang X; Gao H; Yang B; Tian W
PLoS One; 2020; 15(11):e0241241. PubMed ID: 33186371
[TBL] [Abstract][Full Text] [Related]
7. Elevated peroxiredoxin 1, but not NF-E2-related factor 2, is an independent prognostic factor for disease recurrence and reduced survival in stage I non-small cell lung cancer.
Kim JH; Bogner PN; Ramnath N; Park Y; Yu J; Park YM
Clin Cancer Res; 2007 Jul; 13(13):3875-82. PubMed ID: 17606720
[TBL] [Abstract][Full Text] [Related]
8. PPM1D overexpression predicts poor prognosis in non-small cell lung cancer.
Yang H; Gao XY; Li P; Jiang TS
Tumour Biol; 2015 Mar; 36(3):2179-84. PubMed ID: 25412952
[TBL] [Abstract][Full Text] [Related]
9. Down-regulated MicroRNA 148b expression as predictive biomarker and its prognostic significance associated with clinicopathological features in non-small-cell lung cancer patients.
Ghasemkhani N; Shadvar S; Masoudi Y; Talaei AJ; Yahaghi E; Goudarzi PK; Shakiba E
Diagn Pathol; 2015 Sep; 10():164. PubMed ID: 26377406
[TBL] [Abstract][Full Text] [Related]
10. Keap1-Nrf2 Interaction Suppresses Cell Motility in Lung Adenocarcinomas by Targeting the S100P Protein.
Chien MH; Lee WJ; Hsieh FK; Li CF; Cheng TY; Wang MY; Chen JS; Chow JM; Jan YH; Hsiao M; Hua KT; Kuo ML
Clin Cancer Res; 2015 Oct; 21(20):4719-32. PubMed ID: 26078391
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic features and prognostic implications of Gankyrin protein expression in non-small cell lung cancer.
Wang WP; Yan XL; Li WM; Ni YF; Zhao JB; Lu Q; Wang XJ; Sun Y; Chen P; Yan BY; Cui Y; Zhang ZP; Li XF
Pathol Res Pract; 2015 Dec; 211(12):939-47. PubMed ID: 26554593
[TBL] [Abstract][Full Text] [Related]
12. Emerging roles of Nrf2 signal in non-small cell lung cancer.
Tian Y; Liu Q; He X; Yuan X; Chen Y; Chu Q; Wu K
J Hematol Oncol; 2016 Feb; 9():14. PubMed ID: 26922479
[TBL] [Abstract][Full Text] [Related]
13. Beclin 1 and p62 expression in non-small cell lung cancer: relation with malignant behaviors and clinical outcome.
Wang X; Du Z; Li L; Shi M; Yu Y
Int J Clin Exp Pathol; 2015; 8(9):10644-52. PubMed ID: 26617774
[TBL] [Abstract][Full Text] [Related]
14. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results.
Zhao ZH; Wang SF; Yu L; Wang J; Chang H; Yan WL; Zhang J; Fu K
Lung Cancer; 2008 Oct; 62(1):113-9. PubMed ID: 18550205
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of microRNA-126 and microRNA-133b acts as novel predictor biomarkers in progression and metastasis of non small cell lung cancer.
Chen SW; Wang TB; Tian YH; Zheng YG
Int J Clin Exp Pathol; 2015; 8(11):14983-8. PubMed ID: 26823832
[TBL] [Abstract][Full Text] [Related]
17. Investigation of serum miR-411 as a diagnosis and prognosis biomarker for non-small cell lung cancer.
Wang SY; Li Y; Jiang YS; Li RZ
Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4092-4097. PubMed ID: 29028091
[TBL] [Abstract][Full Text] [Related]
18. BPTF biomarker correlates with poor survival in human NSCLC.
Gong YC; Liu DC; Li XP; Dai SP
Eur Rev Med Pharmacol Sci; 2017 Jan; 21(1):102-107. PubMed ID: 28121349
[TBL] [Abstract][Full Text] [Related]
19. Increased high-mobility group A2 correlates with lymph node metastasis and prognosis of non-small cell lung cancer.
Guo X; Shi J; Wen Y; Li M; Li Q; Li X; Li J
Cancer Biomark; 2018 Feb; 21(3):547-555. PubMed ID: 29278873
[TBL] [Abstract][Full Text] [Related]
20. CHIP involves in non-small cell lung cancer prognosis through VEGF pathway.
Tingting Q; Jiao W; Qingfeng W; Yancheng L; Shijun YU; Zhaoqi W; Dongmei S; ShiLong W
Biomed Pharmacother; 2016 Oct; 83():271-276. PubMed ID: 27392029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
